Search

Your search keyword '"Parmiani, Giorgio"' showing total 985 results
Start Over Author "Parmiani, Giorgio"
985 results on '"Parmiani, Giorgio"'

3. Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Author

Ascierto, Paolo A, Atkins, Michael, Bifulco, Carlo, Botti, Gerardo, Cochran, Alistair, Davies, Michael, Demaria, Sandra, Dummer, Reinhard, Ferrone, Soldano, Formenti, Silvia, Gajewski, Thomas F, Garbe, Claus, Khleif, Samir, Kiessling, Rolf, Lo, Roger, Lorigan, Paul, Arthur, Grant Mc, Masucci, Giuseppe, Melero, Ignacio, Mihm, Martin, Palmieri, Giuseppe, Parmiani, Giorgio, Puzanov, Igor, Romero, Pedro, Schilling, Bastian, Seliger, Barbara, Stroncek, David, Taube, Janis, Tomei, Sara, Zarour, Hassane M, Testori, Alessandro, Wang, Ena, Galon, Jérôme, Ciliberto, Gennaro, Mozzillo, Nicola, Marincola, Francesco M, and Thurin, Magdalena

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Immunization, Clinical Research, Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Biomarkers, Tumor, Humans, Immunotherapy, Italy, Melanoma, Tumor Microenvironment, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

The fourth "Melanoma Bridge Meeting" took place in Naples, December 3-6th, 2014. The four topics discussed at this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent advances in tumor biology and immunology have led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded promising results. These include inhibitors of receptor tyrosine kinases (BRAF, MEK, and VEGFR), the phosphatidylinositol 3 kinase (PI3K) pathway [PI3K, AKT, mammalian target of rapamycin (mTOR)], activators of apoptotic pathway, and the cell cycle inhibitors (CDK4/6). Various locoregional interventions including radiotherapy and surgery are still valid approaches in treatment of advanced melanoma that can be integrated with novel therapies. Intrinsic, adaptive and acquired resistance occur with targeted therapy such as BRAF inhibitors, where most responses are short-lived. Given that the reactivation of the MAPK pathway through several distinct mechanisms is responsible for the majority of acquired resistance, it is logical to combine BRAF inhibitors with inhibitors of targets downstream in the MAPK pathway. For example, combination of BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) have been demonstrated to improve survival compared to monotherapy. Application of novel technologies such sequencing have proven useful as a tool for identification of MAPK pathway-alternative resistance mechanism and designing other combinatorial therapies such as those between BRAF and AKT inhibitors. Improved survival rates have also been observed with immune-targeted therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demonstrate clinical benefit in patients with melanoma as well. These agents are being studied in combination with targeted therapies in attempt to produce longer-term responses than those more typically seen with targeted therapy. Other combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates for this patient population. This meeting's specific focus was on advances in combination of targeted therapy and immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment response was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma.

Published
2015

4. Consensus nomenclature for CD8+ T cell phenotypes in cancer

Author

Apetoh, Lionel, Smyth, Mark J, Drake, Charles G, Abastado, Jean-Pierre, Apte, Ron N, Ayyoub, Maha, Blay, Jean-Yves, Bonneville, Marc, Butterfield, Lisa H, Caignard, Anne, Castelli, Chiara, Cavallo, Federica, Celis, Esteban, Chen, Lieping, Colombo, Mario P, Comin-Anduix, Begoña, Coukos, Georges, Dhodapkar, Madhav V, Dranoff, Glenn, Frazer, Ian H, Fridman, Wolf-Hervé, Gabrilovich, Dmitry I, Gilboa, Eli, Gnjatic, Sacha, Jäger, Dirk, Kalinski, Pawel, Kaufman, Howard L, Kiessling, Rolf, Kirkwood, John, Knuth, Alexander, Liblau, Roland, Lotze, Michael T, Lugli, Enrico, Marincola, Francesco, Melero, Ignacio, Melief, Cornelis J, Mempel, Thorsten R, Mittendorf, Elizabeth A, Odun, Kunle, Overwijk, Willem W, Palucka, Anna Karolina, Parmiani, Giorgio, Ribas, Antoni, Romero, Pedro, Schreiber, Robert D, Schuler, Gerold, Srivastava, Pramod K, Tartour, Eric, Valmori, Danila, van der Burg, Sjoerd H, van der Bruggen, Pierre, van den Eynde, Benoît J, Wang, Ena, Zou, Weiping, Whiteside, Theresa L, Speiser, Daniel E, Pardoll, Drew M, Restifo, Nicholas P, and Anderson, Ana C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, 2.1 Biological and endogenous factors, Aetiology, anergy, anticancer immunity, CD8(+) T cells, cytotoxicity, exhaustion, effector, IFN gamma, senescence, stemness, CD8+ T cells, IFNγ, Oncology and carcinogenesis
Abstract

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

Published
2015

5. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, Bernard A, Schendel, Dolores J, Butterfield, Lisa H, Aamdal, Steinar, Allison, James P, Ascierto, Paolo, Atkins, Michael B, Bartunkova, Jirina, Bergmann, Lothar, Berinstein, Neil, Bonorino, Cristina C, Borden, Ernest, Bramson, Jonathan L, Britten, Cedrik M, Cao, Xuetao, Carson, William E, Chang, Alfred E, Characiejus, Dainius, Choudhury, A Raja, Coukos, George, de Gruijl, Tanja, Dillman, Robert O, Dolstra, Harry, Dranoff, Glenn, Durrant, Lindy G, Finke, James H, Galon, Jerome, Gollob, Jared A, Gouttefangeas, Cécile, Grizzi, Fabio, Guida, Michele, Håkansson, Leif, Hege, Kristen, Herberman, Ronald B, Hodi, F Stephen, Hoos, Axel, Huber, Christoph, Hwu, Patrick, Imai, Kohzoh, Jaffee, Elizabeth M, Janetzki, Sylvia, June, Carl H, Kalinski, Pawel, Kaufman, Howard L, Kawakami, Koji, Kawakami, Yutaka, Keilholtz, Ulrich, Khleif, Samir N, Kiessling, Rolf, Kotlan, Beatrix, Kroemer, Guido, Lapointe, Rejean, Levitsky, Hyam I, Lotze, Michael T, Maccalli, Cristina, Maio, Michele, Marschner, Jens-Peter, Mastrangelo, Michael J, Masucci, Giuseppe, Melero, Ignacio, Melief, Cornelius, Murphy, William J, Nelson, Brad, Nicolini, Andrea, Nishimura, Michael I, Odunsi, Kunle, Ohashi, Pamela S, O'Donnell-Tormey, Jill, Old, Lloyd J, Ottensmeier, Christian, Papamichail, Michael, Parmiani, Giorgio, Pawelec, Graham, Proietti, Enrico, Qin, Shukui, Rees, Robert, Ribas, Antoni, Ridolfi, Ruggero, Ritter, Gerd, Rivoltini, Licia, Romero, Pedro J, Salem, Mohamed L, Scheper, Rik J, Seliger, Barbara, Sharma, Padmanee, Shiku, Hiroshi, Singh-Jasuja, Harpreet, Song, Wenru, Straten, Per, Tahara, Hideaki, Tian, Zhigang, van Der Burg, Sjoerd H, von Hoegen, Paul, Wang, Ena, Welters, Marij JP, Winter, Hauke, Withington, Tara, Wolchok, Jedd D, Xiao, Weihua, and Zitvogel, Laurence

Abstract

Abstract Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

Published
2011

9. Data from Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

Author

Di Tomaso, Tiziano, primary, Mazzoleni, Stefania, primary, Wang, Ena, primary, Sovena, Gloria, primary, Clavenna, Daniela, primary, Franzin, Alberto, primary, Mortini, Pietro, primary, Ferrone, Soldano, primary, Doglioni, Claudio, primary, Marincola, Francesco M., primary, Galli, Rossella, primary, Parmiani, Giorgio, primary, and Maccalli, Cristina, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

Author

Di Tomaso, Tiziano, primary, Mazzoleni, Stefania, primary, Wang, Ena, primary, Sovena, Gloria, primary, Clavenna, Daniela, primary, Franzin, Alberto, primary, Mortini, Pietro, primary, Ferrone, Soldano, primary, Doglioni, Claudio, primary, Marincola, Francesco M., primary, Galli, Rossella, primary, Parmiani, Giorgio, primary, and Maccalli, Cristina, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1

Author

Maccalli, Cristina, primary, Di Cristanziano, Veronica, primary, Fodale, Valentina, primary, Corsi, Domenico, primary, D'Agostino, Giuseppina, primary, Petrangeli, Valentina, primary, Laurenti, Luca, primary, Guida, Sofia, primary, Mazzocchi, Arabella, primary, Arienti, Flavio, primary, Perrone, Maria P., primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, Zagonel, Vittorina, primary, Tartaglia, Marco, primary, Parmiani, Giorgio, primary, and Belardelli, Filippo, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

21. Data from Reconstitution of Human Telomerase Reverse Transcriptase Expression Rescues Colorectal Carcinoma Cells from In vitro Senescence: Evidence against Immortality as a Constitutive Trait of Tumor Cells

Author

Dalerba, Piero, primary, Guiducci, Cristiana, primary, Poliani, Pietro Luigi, primary, Cifola, Ingrid, primary, Parenza, Mariella, primary, Frattini, Milo, primary, Gallino, Gianfrancesco, primary, Carnevali, Ileana, primary, Di Giulio, Ilvia, primary, Andreola, Salvatore, primary, Lombardo, Claudia, primary, Rivoltini, Licia, primary, Schweighoffer, Tamás, primary, Belli, Filiberto, primary, Colombo, Mario P., primary, Parmiani, Giorgio, primary, and Castelli, Chiara, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors

Author

Di Pucchio, Tiziana, primary, Pilla, Lorenzo, primary, Capone, Imerio, primary, Ferrantini, Maria, primary, Montefiore, Enrica, primary, Urbani, Francesca, primary, Patuzzo, Roberto, primary, Pennacchioli, Elisabetta, primary, Santinami, Mario, primary, Cova, Agata, primary, Sovena, Gloria, primary, Arienti, Flavio, primary, Lombardo, Claudia, primary, Lombardi, Arianna, primary, Caporaso, Patrizia, primary, D'Atri, Stefania, primary, Marchetti, Paolo, primary, Bonmassar, Enzo, primary, Parmiani, Giorgio, primary, Belardelli, Filippo, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

24. Data from Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes

Author

Calcinotto, Arianna, primary, Filipazzi, Paola, primary, Grioni, Matteo, primary, Iero, Manuela, primary, De Milito, Angelo, primary, Ricupito, Alessia, primary, Cova, Agata, primary, Canese, Rossella, primary, Jachetti, Elena, primary, Rossetti, Monica, primary, Huber, Veronica, primary, Parmiani, Giorgio, primary, Generoso, Luca, primary, Santinami, Mario, primary, Borghi, Martina, primary, Fais, Stefano, primary, Bellone, Matteo, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Methods from Reconstitution of Human Telomerase Reverse Transcriptase Expression Rescues Colorectal Carcinoma Cells from In vitro Senescence: Evidence against Immortality as a Constitutive Trait of Tumor Cells

Author

Dalerba, Piero, primary, Guiducci, Cristiana, primary, Poliani, Pietro Luigi, primary, Cifola, Ingrid, primary, Parenza, Mariella, primary, Frattini, Milo, primary, Gallino, Gianfrancesco, primary, Carnevali, Ileana, primary, Di Giulio, Ilvia, primary, Andreola, Salvatore, primary, Lombardo, Claudia, primary, Rivoltini, Licia, primary, Schweighoffer, Tamás, primary, Belli, Filiberto, primary, Colombo, Mario P., primary, Parmiani, Giorgio, primary, and Castelli, Chiara, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1, Figures 1-8 from Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes

Author

Calcinotto, Arianna, primary, Filipazzi, Paola, primary, Grioni, Matteo, primary, Iero, Manuela, primary, De Milito, Angelo, primary, Ricupito, Alessia, primary, Cova, Agata, primary, Canese, Rossella, primary, Jachetti, Elena, primary, Rossetti, Monica, primary, Huber, Veronica, primary, Parmiani, Giorgio, primary, Generoso, Luca, primary, Santinami, Mario, primary, Borghi, Martina, primary, Fais, Stefano, primary, Bellone, Matteo, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Methods, Figure 1 Legend , Tables 1-2 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

34. Data from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

38. “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

Author

Maio, Michele, Bertocci, Erica, Fazio, Carolina, Chiarucci, Carla, Cutaia, Ornella, Scala, Elisa, Giacobini, Gianluca, Lofiego, Maria Fortunata, Fonsatti, Ester, Maccalli, Cristina, Nicolay, Hugues J. M. G., Parmiani, Giorgio, Anichini, Andrea, Di Giacomo, Anna Maria, Sica, Antonio, Calcinotto, Arianna, Seliger, Barbara, Buccione, Carla, Garlanda, Cecilia, Martinoli, Chiara, Pozzi, Chiara, Huber, Christoph, Chartash, Elliot, Carbone, Ennio, Marincola, Francesco M., Zuccolotto, Gaia, Schuler, Gerold, Oliveira, Giacomo, Corna, Gianfranca, Rammensee, Hans-Georg, Cuillerot, Jean-Marie, Rivoltini, Licia, Moretta, Lorenzo, Calabrò, Luana, Tagliamonte, Maria, Figini, Mariangela, Squadrito, Mario Leonardo, Colombo, Mario P., Giordano, Michael, Azab, Mohammad, Nistico’, Paola, thor Straten, Per, Coulie, Pierre, Ibrahim, Ramy, Huber, Samuel, Monfardini, Silvio, Ferrone, Soldano, Sahin, Ugur, Bronte, Vincenzo, Fridman, Wolf H., Trajanoski, Zlatko, and NIBIT

Published
2016
Full Text
View/download PDF

41. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes

Author

Maccalli, Cristina, Romano, Michele C, Mennonna, Daniele, Garavaglia, Claudio, Capocefalo, Filippo, Bordoni, Roberta, Severgnini, Marco, De Bellis, Gianluca, Sidney, John, Sette, Alessandro, Gori, Alessandro, Longhi, Renato, Braga, Marco, Ghirardelli, Luca, Baldari, Ludovica, Orsenigo, Elena, Albarello, Luca, Zino, Elisabetta, Fleischhauer, Katharina, Mazzola, Gina, Ferrero, Norma, Amoroso, Antonio, Casorati, Giulia, Parmiani, Giorgio, and Dellabona, Paolo

Published
2017
Full Text
View/download PDF

47. A Microsatellite in the Coding Sequence of HLA-A/B Is a Mutation Hotspot in Colon Cancer With Microsatellite Instability

Author

Raab, William J., primary, Mazzocchi, Arabella, additional, Radice, Paolo, additional, Sahoo, Debashis, additional, Castelli, Chiara, additional, Dalerba, Piero, additional, Behroozikhah, Mahdi, additional, Lombardo, Claudia, additional, Novellino, Luisa, additional, Cifola, Ingrid, additional, Casati, Chiara, additional, Longa, Elena Dalla, additional, Schweighoffer, Tamás, additional, Arienti, Flavio, additional, and Parmiani, Giorgio, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results